Infectious disease specialist ExeVir Bio has appointed Viki Bockstal as chief scientific officer and Caroline Sagaert as head of operations, with Jean-Philippe Bultot taking over as head of finance.
ExeVir said Dr Bockstal has “extensive experience” in infectious diseases, immunology, and viral vaccine technology from her previous R&D work at Janssen.
Formerly a senior finance manager at Bone Therapeutics, Mr Bultot has been ExeVir’s controller and financial operations lead since October 2021.
Chief executive Torsten Mummenbrauer said: “We have come so far since 2020, including securing $20 million in major grants, closing a $50 million Series A, raising a $27.5 million venture debt with the EIB and completing a Phase Ia and Ib clinical study.”
Fiona du Monceau will step down as the current chief operating officer and chief finance officer and will become an observer on the board.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze